SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-20-033053
Filing Date
2020-10-23
Accepted
2020-10-23 17:01:56
Documents
43
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0920_actiniumpharma.htm 10-Q 642158
2 CERTIFICATION f10q0920ex31-1_actinium.htm EX-31.1 11239
3 CERTIFICATION f10q0920ex31-2_actinium.htm EX-31.2 10568
4 CERTIFICATION f10q0920ex32-1_actinium.htm EX-32.1 4304
5 CERTIFICATION f10q0920ex32-2_actinium.htm EX-32.2 4392
  Complete submission text file 0001213900-20-033053.txt   2739878

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE atnm-20200930.xml EX-101.INS 337819
7 XBRL SCHEMA FILE atnm-20200930.xsd EX-101.SCH 37417
8 XBRL CALCULATION FILE atnm-20200930_cal.xml EX-101.CAL 26435
9 XBRL DEFINITION FILE atnm-20200930_def.xml EX-101.DEF 158281
10 XBRL LABEL FILE atnm-20200930_lab.xml EX-101.LAB 303738
11 XBRL PRESENTATION FILE atnm-20200930_pre.xml EX-101.PRE 171444
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

IRS No.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36374 | Film No.: 201258350
SIC: 2834 Pharmaceutical Preparations